ReviewNature reviews. Cardiology2018
Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases.
Review in Nature reviews. Cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Cardiovascular risk in axial spondyloarthritis-a systematic review.Clinical rheumatology · 2023Pooled it
- Cardiac Rehabilitation for Cardiovascular Risk Modification in Patients With Rheumatoid Arthritis and Hypertension: A Randomized Controlled Trial.International journal of rheumatic diseases · 2026Trial
- Unattended compared to traditional blood pressure measurement in patients with rheumatoid arthritis: a randomised cross-over study.Annals of medicine · 2021Trial
- Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis.Scientific reports · 2021Trial
- Differential laboratory monitoring in autoimmune disease: a matched case-control study from Qatar primary care.Journal of translational medicine · 2026Article
- Metabolic Improvement Mediates the Causal Relationship Between GLP-1 Receptor Agonists and Myocardial Infarction: A Mendelian Randomization and Mediation Analysis Study.Diabetes care · 2026Article
- Potential association between IL-17A inhibition and blood pressure reduction in patients with axial spondyloarthritis.Frontiers in immunology · 2026Article
- Metabolic Consequences of Rheumatoid Arthritis.Arthritis care & research · 2025Review
- Cardiovascular risk in axial spondyloarthritis: the interplay of inflammation, traditional risk factors, and management strategies.Rheumatology international · 2025Review
- Machine learning based association between inflammation indicators (NLR, PLR, NPAR, SII, SIRI, and AISI) and all-cause mortality in arthritis patients with hypertension: NHANES 1999-2018.Frontiers in public health · 2025Article
- Body shape index: an index for early target organ damage in hypertension.American journal of translational research · 2025Article
- Cardio-Rheumatology Insights Into Hypertension: Intersection of Inflammation, Arteries, and Heart.American journal of hypertension · 2024Review
- Sex Differences in Cardiovascular Risk Profiles of Patients with Rheumatoid Arthritis: Results from an Italian Multicentre Cohort.Journal of clinical medicine · 2024Article
- Autoimmune diseases and atherosclerotic cardiovascular disease.Nature reviews. Cardiology · 2024Review
- Hypertension in connective tissue disease.Journal of human hypertension · 2024Review
- Establishment and evaluation of a risk prediction model for coronary heart disease in primary Sjögren's syndrome based on peripheral blood IL-6 and Treg percentages.Frontiers in immunology · 2024Article
- Tumor Necrosis Factor Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis.Clinical reviews in allergy & immunology · 2023Review
- Risk factors for cardiovascular disease in primary Sjögren's syndrome (pSS): a 20-year follow-up study.Clinical rheumatology · 2023Article
- Related factors of renal injury in primary Sjögren's syndrome.Immunity & ageing : I & A · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence for the increased risk of cardiovascular morbidity and mortality in patients with chronic inflammatory and systemic autoimmune diseases has accumulated during the past 15 years. In these patients, an interplay between several mechanisms, including premature acceleration of subclinical atherosclerotic damage, inflammation, and dysregulation of the immune system, is involved in the induction and progression of atherosclerosis. Moreover, traditional cardiovascular risk factors are also likely to contribute, at least in part, to the excess cardiovascular risk. Among traditional cardiovascular risk factors, hypertension is an important predictor of cardiovascular events in the general population and in patients with chronic inflammatory and autoimmune diseases. Evidence supports the idea that the pathogenic mechanisms underlying the increased blood pressure in these diseases are multifactorial and not only related to the mechanical injury of the arterial wall. In particular, chronic inflammation and immune-mediated mechanisms have been demonstrated to affect blood-pressure control in patients with systemic autoimmune disease. In this Review, we discuss the available evidence on the relationship between hypertension and autoimmune diseases, and describe the multiple factors that might affect blood-pressure control in patients with chronic inflammatory and systemic autoimmune diseases. We also discuss the effect of hypertension and antirheumatic therapies on cardiovascular outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.